| Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression M Bustoros, R Sklavenitis-Pistofidis, J Park, R Redd, B Zhitomirsky, ... Journal of Clinical Oncology 38 (21), 2380, 2020 | 143 | 2020 |
| Genome instability in multiple myeloma CJ Neuse, OC Lomas, C Schliemann, YJ Shen, S Manier, M Bustoros, ... Leukemia 34 (11), 2887-2897, 2020 | 90 | 2020 |
| Progression risk stratification of asymptomatic Waldenström macroglobulinemia M Bustoros, R Sklavenitis-Pistofidis, P Kapoor, CJ Liu, E Kastritis, ... Journal of Clinical Oncology 37 (16), 1403, 2019 | 82 | 2019 |
| Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma C Liu, IM Ghobrial, M Bustoros, K Reyes, K Hornburg, AZ Badros, ... Blood 132 (Supplement 1), 154-154, 2018 | 33 | 2018 |
| Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes M Bustoros, S Anand, R Sklavenitis-Pistofidis, R Redd, EM Boyle, ... Nature communications 13 (1), 3449, 2022 | 14 | 2022 |
| Bone marrow biopsy in low‐risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group M Bustoros, E Kastritis, R Sklavenitis‐Pistofidis, CJ Liu, K Hornburg, ... American Journal of Hematology 94 (5), E146-E149, 2019 | 11 | 2019 |
| Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. M Bustoros, R Sklavenitis-Pistofidis, J Park, R Redd, B Zhitomirsky, ... Clinical Lymphoma Myeloma and Leukemia 19 (10), e5-e6, 2019 | 1 | 2019 |
| Die Bedeutung von cfDNA im 24h-Urin beim Multiplen Myelom CJ Neuse PQDT-Global, 2023 | | 2023 |
| Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes S Anand, M Bustoros, R Sklavenitis-Pistofidis, RA Redd, EM Boyle, YT Tai, ... Blood 138, 723, 2021 | | 2021 |
| Genomic profiling of smoldering multiple myeloma classifies distinct molecular groups S Anand, M Bustoros, F Aguet, R Sklavenitis-Pistofidis, R Redd, ... Cancer Research 81 (13_Supplement), 2240-2240, 2021 | | 2021 |
| Progression risk stratification of Asymptomatic Waldenström Macroglobulinemia R Sklavenitis-Pistofidis, M Bustoros, P Kapoor, CJ Liu, E Kastritis, ... Clinical Lymphoma, Myeloma and Leukemia 19 (10), e38-e39, 2019 | | 2019 |
| Progression Risk-Based Classification of Asymptomatic Waldenström Macroglobulinemia M Bustoros, R Sklavenitis-Pistofidis, C Liu, E Kastritis, G Fell, K Hornburg, ... Blood 132 (Supplement 1), 150-150, 2018 | | 2018 |
